TABLE 3.
Duration of Protection and Reduction in Rates of Rotavirus-Coded Hospitalization Among Children Who Received at Least 1 Dose of RV5 Versus Unvaccinated Children, According to Agea
Age (mo)b | Rotavirus-Coded Diarrhea | ||
---|---|---|---|
Hospitalization Rate, n/10 000 PY |
Rate Reduction (95% CI), % | ||
Vax + | Vax − | ||
3–11 | 1 | 8 | 87 (85–90) |
12–23 | 1 | 19 | 87 (84–89) |
24–35 | 2 | 11 | 86 (83–89) |
36–47 | 0 | 5 | NA |
48–59 | 1 | 5 | 81 (75–86) |
NA, not applicable; PY, person-year; Vax +, vaccinated; Vax −, unvaccinated.
Children who were age-eligible for the RV5 vaccine as of February 3, 2006, when RV5 was first recommended (ie, age less than the first-dose upper limit of 14 wk and 6 d when RV5 was licensed on February 3, 2006) and who were continuously enrolled in their insurance plan for at least 3 mo). Vaccination status was determined by the presence or absence of a current procedural terminology code for receipt of at least 1 dose of RV5. Children who were either from states with universal vaccination programs or had received mixed vaccine schedules with both RV1 and RV5 doses were excluded.
Age at hospitalization for a diarrhea-associated event.